For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $155.63 in the prior trading day, Neurocrine Biosciences, Inc (NASDAQ: NBIX) closed at $154.75, down -0.57%. In other words, the price has decreased by -$0.57 from its previous closing price. On the day, 0.94 million shares were traded. NBIX stock price reached its highest trading level at $156.46 during the session, while it also had its lowest trading level at $153.3.
Ratios:
Our goal is to gain a better understanding of NBIX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.84 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 26.01. For the most recent quarter (mrq), Quick Ratio is recorded 3.27 and its Current Ratio is at 3.38. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In the most recent recommendation for this company, Citigroup on October 21, 2025, initiated with a Buy rating and assigned the stock a target price of $175. On July 21, 2025, Truist started tracking the stock assigning a Buy rating and target price of $163. On July 10, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $182.Goldman initiated its Buy rating on July 10, 2025, with a $182 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 08 ’25 when Lippoldt Darin sold 4,376 shares for $159.65 per share. The transaction valued at 698,615 led to the insider holds 43,405 shares of the business.
DARIN LIPPOLDT bought 4,376 shares of NBIX for $680,512 on Dec 08 ’25. On Dec 03 ’25, another insider, LYONS GARY A, who serves as the Director of the company, sold 15,000 shares for $152.61 each. As a result, the insider received 2,289,082 and left with 120,482 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NBIX now has a Market Capitalization of 15429456896 and an Enterprise Value of 14794356736. As of this moment, Neurocrine’s Price-to-Earnings (P/E) ratio for their current fiscal year is 36.96, and their Forward P/E ratio for the next fiscal year is 21.86. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.61. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.75 while its Price-to-Book (P/B) ratio in mrq is 5.14. Its current Enterprise Value per Revenue stands at 5.515 whereas that against EBITDA is 25.955.
Stock Price History:
The Beta on a monthly basis for NBIX is 0.28, which has changed by 0.22138906 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, NBIX has reached a high of $160.18, while it has fallen to a 52-week low of $84.23. The 50-Day Moving Average of the stock is 6.91%, while the 200-Day Moving Average is calculated to be 20.22%.
Shares Statistics:
The stock has traded on average 958.08K shares per day over the past 3-months and 853080 shares per day over the last 10 days, according to various share statistics. A total of 99.70M shares are outstanding, with a floating share count of 97.07M. Insiders hold about 2.64% of the company’s shares, while institutions hold 98.34% stake in the company. Shares short for NBIX as of 1764288000 were 3987908 with a Short Ratio of 4.16, compared to 1761868800 on 4114577. Therefore, it implies a Short% of Shares Outstanding of 3987908 and a Short% of Float of 5.33.
Earnings Estimates
Current recommendations for the stock of the company come from 16.0 analysts. The consensus estimate for the next quarter is $1.99, with high estimates of $2.45 and low estimates of $1.77.
Analysts are recommending an EPS of between $7.34 and $6.47 for the fiscal current year, implying an average EPS of $6.89. EPS for the following year is $9.15, with 17.0 analysts recommending between $11.05 and $7.14.
Revenue Estimates
25 analysts predict $805M in revenue for. The current quarter. It ranges from a high estimate of $829.11M to a low estimate of $760.8M. As of. The current estimate, Neurocrine Biosciences, Inc’s year-ago sales were $627.7MFor the next quarter, 25 analysts are estimating revenue of $773.97M. There is a high estimate of $848.49M for the next quarter, whereas the lowest estimate is $722.7M.
A total of 25 analysts have provided revenue estimates for NBIX’s current fiscal year. The highest revenue estimate was $2.88B, while the lowest revenue estimate was $2.79B, resulting in an average revenue estimate of $2.86B. In the same quarter a year ago, actual revenue was $2.36BBased on 24 analysts’ estimates, the company’s revenue will be $3.38B in the next fiscal year. The high estimate is $3.65B and the low estimate is $3.11B.
